Soquelitinib Shows Promise in Atopic Dermatitis Trial
Corvus Pharmaceuticals released interim Phase 1 data for soquelitinib, an oral ITK inhibitor, in patients with moderate to severe...
Corvus Pharmaceuticals released interim Phase 1 data for soquelitinib, an oral ITK inhibitor, in patients with moderate to severe...
UTRx Inc. submitted an Investigational New Drug (IND) application to the FDA for UTRxM1-18, a novel therapeutic targeting c-MYC...
Kriya Therapeutics presented preclinical data at the ARVO Annual Meeting for KRIYA-825, a gene therapy candidate for Geographic Atrophy...
Spherix Global Insights’ analysis of over 2,300 patient charts reveals a global shift in IgA nephropathy (IgAN) treatment, driven...
Yamo Pharmaceuticals announced positive Phase 2 trial results for L1-79, a drug targeting core autism spectrum disorder (ASD) symptoms,...
PDS Biotechnology Corporation announced preclinical data on its investigational Infectimune®-based flu vaccine at the IMMUNOLOGY2025™ Annual Meeting. Studies conducted...
Cognition Therapeutics announced topline results from its Phase 2 MAGNIFY trial of zervimesine, an oral drug for geographic atrophy...
Ashvattha Therapeutics announced positive interim Phase 2 results for its subcutaneously administered nanomedicine, migaldendranib (MGB), designed to treat retinal...
A real-world study published in JCO Precision Oncology suggests that Myriad Genetics’ RiskScore tool, integrated into its MyRisk Hereditary...
Syndax Pharmaceuticals announced positive Phase 2 trial results for revumenib, a menin inhibitor, in patients with relapsed or refractory...